IR@PKUHSC  > 北京大学第三临床医学院
学科主题临床医学
High-Dose N-Acetylcysteine in the Prevention of COPD Exacerbations: Rationale and Design of the PANTHEON Study
Zheng, Jin-Ping1; Wen, Fu-Qiang2; Bai, Chun-Xue3; Wan, Huan-Ying4; Kang, Jian5; Chen, Ping6; Yao, Wan-Zhen7; Ma, Li-Jun8; Xia, Qi-kui9; Gao, Yi1; Zhong, Nan-Shan1; PANTHEON Study Comm1
关键词Copd Exacerbation N-acetylcysteine Ics Quality Of Life Mucolytics Anti-inflammation Anti-oxidant
刊名COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
2013-04-01
DOI10.3109/15412555.2012.732628
10期:2页:164-171
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Respiratory System
研究领域[WOS]Respiratory System
关键词[WOS]OBSTRUCTIVE PULMONARY-DISEASE ; ACETYL-L-CYSTEINE ; IN-VITRO ; TRIAL ; CARBOCISTEINE ; INFLAMMATION ; BRONCHITIS ; RISK
英文摘要

Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation; from a pathophysiological point of view it involves many components, including mucus hypersecretion, oxidative stress and inflammation. N-acetylcysteine (NAC) is a mucolytic agent with antioxidant and anti-inflammatory properties. Long-term efficacy of NAC 600mg/d in COPD is controversial; a dose-effect relationship has been demonstrated, but at present it is not known whether a higher dose provides clinical benefits. The PANTHEON Study is a prospective, ICS stratified, randomized, double-blind, placebo-controlled, parallel-group, multi-center trial designed to assess the efficacy and safety of high-dose (1200 mg/daily) NAC treatment for one year in moderate-to-severe COPD patients. The primary endpoint is the annual exacerbation rate. Secondary endpoints include recurrent exacerbations hazard ratio, time to first exacerbation, as well as quality of life and pulmonary function. The hypothesis, design and methodology are described and baseline characteristics of recruited patients are presented. 1006 COPD patients (444 treated with maintenance ICS, 562 ICS naive, aged 66.27 +/- 8.76 yrs, average post-bronchodilator FEV1 48.95 +/- 11.80 of predicted) have been randomized at 34 hospitals in China. Final results of this study will provide objective data on the effects of high-dose (1200 mg/daily) long-term NAC treatment in the prevention of COPD exacerbations and other outcome variables.

语种英语
WOS记录号WOS:000316954500007
资助机构Hainan Zambon Pharmaceutical Co., Ltd.
引用统计
被引频次:8[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/50965
专题北京大学第三临床医学院
作者单位1.Fudan Univ, Zhongshan Hosp, Shanghai 200433, Peoples R China
2.China Med Univ, Affiliated Hosp 1, Shenyang, Peoples R China
3.Shenyang PLA Gen Hosp, Shenyang, Peoples R China
4.Peking Univ, Hosp 3, Beijing 100871, Peoples R China
5.Henan Prov Peoples Hosp, Zhengzhou, Peoples R China
6.Fudan Univ, Publ Hlth Univ, Shanghai 200433, Peoples R China
7.Sichuan Univ, Huaxi Hosp, Chengdu 610064, Peoples R China
8.Guangzhou Med Univ, State Key Lab Resp Dis, Affiliated Hosp 1, Guangzhou 510120, Guangdong, Peoples R China
9.Shanghai Jiao Tong Univ, Rui Jin Hosp, Sch Med, Shanghai, Peoples R China
推荐引用方式
GB/T 7714
Zheng, Jin-Ping,Wen, Fu-Qiang,Bai, Chun-Xue,et al. High-Dose N-Acetylcysteine in the Prevention of COPD Exacerbations: Rationale and Design of the PANTHEON Study[J]. COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,2013,10(2):164-171.
APA Zheng, Jin-Ping.,Wen, Fu-Qiang.,Bai, Chun-Xue.,Wan, Huan-Ying.,Kang, Jian.,...&PANTHEON Study Comm.(2013).High-Dose N-Acetylcysteine in the Prevention of COPD Exacerbations: Rationale and Design of the PANTHEON Study.COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,10(2),164-171.
MLA Zheng, Jin-Ping,et al."High-Dose N-Acetylcysteine in the Prevention of COPD Exacerbations: Rationale and Design of the PANTHEON Study".COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE 10.2(2013):164-171.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zheng, Jin-Ping]的文章
[Wen, Fu-Qiang]的文章
[Bai, Chun-Xue]的文章
百度学术
百度学术中相似的文章
[Zheng, Jin-Ping]的文章
[Wen, Fu-Qiang]的文章
[Bai, Chun-Xue]的文章
必应学术
必应学术中相似的文章
[Zheng, Jin-Ping]的文章
[Wen, Fu-Qiang]的文章
[Bai, Chun-Xue]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。